Abstract
Insulin pump therapy has become the preferential treatment for type 1 diabetes (T1D) as it mimics the physiological secretion of insulin better than multiple daily injections. However, not all patients improve with insulin pump therapy. This study aims to determine the predictors of the effectiveness of insulin pumps in T1D. We conducted a retrospective observational study of patients who started insulin pumps. Data from four timepoints (before, at 6, 12, and 36 months) were evaluated for outcomes of glycemic control and safety. The association of baseline predictors with outcomes was analyzed using linear and logistic regression models. We evaluated 136 patients (57.4% females, age 36 ± 12 years, duration of T1D 14 ± 9 years). During the follow-up, there was a mean decrease of HbA1c of 0.9 ± 1.2%. The improvement in HbA1c was independent of sex, age, and duration of T1D. Higher baseline HbA1c, family history of diabetes, and not being treated with statins were predictors of improvement in HbA1c. Not being treated with statins and higher baseline HbA1c predicted improvement in HbA1c without worsening hypoglycemia. History of hypoglycemia was a predictor of severe hypoglycemia. Family history, higher baseline HbA1c, and psychological/psychiatric disorders were predictors of ketoacidosis. Benefits of insulin pump were independent of sex, age, and duration of T1D. Baseline HbA1c, family history of diabetes, treatment with statins, history of hypoglycemia, and psychological/psychiatric disorders were predictors of outcomes, and may allow the identification of patients who benefit most from insulin pump therapy or who are at increased risk of complications.
Highlights
Type 1 Diabetes (T1D) represents 10–15% of all diabetes cases [1]
Insulin pump therapy has become the preferential treatment for type 1 diabetes (T1D) as it mimics the physiological secretion of insulin better than multiple daily injections
Benefits of insulin pump were independent of sex, age, and duration of T1D
Summary
Type 1 Diabetes (T1D) represents 10–15% of all diabetes cases [1]. Patients with T1D are at risk of acute (diabetic ketoacidosis and severe hypoglycemia) and chronic complications of diabetes (macrovascular, microvascular and other complications). Proper management of hyperglycemia is essential to decrease the risk of acute and long-term complications [4,5,6]. Intensive glucose treatment decreases the risk of microvascular complications [7] and may decrease the risk of macrovascular complications on the long-term follow-up. [8] most patients with T1D have poor glycemic control [9], and acute and chronic complications are still frequent in patients with T1D [10, 11] Intensive glucose treatment decreases the risk of microvascular complications [7] and may decrease the risk of macrovascular complications on the long-term follow-up. [8] most patients with T1D have poor glycemic control [9], and acute and chronic complications are still frequent in patients with T1D [10, 11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
